Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,474 Financial Services 1,896 Healthcare 1,114 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 336 Consumer Defensive 248 Communication Services 212 Utilities 185 Energy 165 Real Estate 81

115 stocks · page 2 of 2

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Deeply undervalued

Discount 32% Return to IV: +47.9%

Owner yield 5.3% 10-yr IRR 12.3% · moderate

Market implies +3.3%/yr vs model +10.4% · below model

Model IV$108.65

Discount 16% Return to IV: +18.4%

Owner yield 4.2% 10-yr IRR 5.9% · moderate

Market implies +3.0%/yr vs model +6.1% · below model

Deeply overvalued

Premium +262% Return to IV: -72.3%

Owner yield 2.2% 10-yr IRR -0.7% · moderate

Market implies +26.4%/yr vs model +8.2% · above model

Deeply overvalued

Model IV$118.39

Premium +39% Return to IV: -28.2%

Owner yield 5.8% 10-yr IRR 6.9% · steady

Market implies +6.3%/yr vs model +2.0% · above model

Merck & Co., Inc.

Model IV$120.25

Premium +24% Return to IV: -19.6%

Owner yield 3.3% 10-yr IRR 4.4% · moderate

Market implies +9.4%/yr vs model +8.2% · in line

Market implies +76.6%/yr vs model +2.0% · above model

METTLER TOLEDO INTERNATIONAL INC/

Deeply overvalued

Model IV$792.57

Premium +80% Return to IV: -44.6%

Owner yield 2.9% 10-yr IRR 2.2% · moderate

Market implies +14.2%/yr vs model +7.5% · above model

NEUROCRINE BIOSCIENCES INC

Deeply undervalued

Model IV$244.63

Discount 41% Return to IV: +69.9%

Owner yield 3.8% 10-yr IRR 11.0% · grower

Market implies +9.1%/yr vs model +21.2% · below model

Deeply overvalued

Premium +316% Return to IV: -76.0%

Market implies +18.2%/yr vs model +38.6% · below model

NOVO NORDISK A S

Deeply undervalued

Model IV$212.96

Discount 34% Return to IV: +51.1%

Owner yield 5.4% 10-yr IRR 10.1% · moderate

Market implies +1.0%/yr vs model +7.4% · below model

BeOne Medicines Ltd.

Market implies +23.5%/yr vs model +46.0% · below model

ONTO INNOVATION INC.

Owner yield 1.6% 10-yr IRR -7.4% · steady

Market implies +30.5%/yr vs model +3.0% · above model

Deeply overvalued

Model IV$221.14

Premium +44% Return to IV: -30.6%

Market implies -4.3%/yr vs model +17.1% · below model

Discount 10% Return to IV: +10.9%

Owner yield 5.0% 10-yr IRR 5.7% · steady

Market implies +1.3%/yr vs model +3.0% · in line

KONINKLIJKE PHILIPS NV

RedHill Biopharma Ltd.

DR REDDYS LABORATORIES LTD

REGENERON PHARMACEUTICALS, INC.

Deeply overvalued

Model IV$601.17

Premium +33% Return to IV: -24.7%

Owner yield 4.5% 10-yr IRR 4.9% · steady

Market implies +7.0%/yr vs model +3.8% · above model

Deeply undervalued

Model IV$375.92

Discount 41% Return to IV: +68.1%

Owner yield 3.6% 10-yr IRR 8.0% · moderate

Market implies +3.4%/yr vs model +11.9% · below model

Roivant Sciences Ltd.

Market implies +143.0%/yr vs model +2.0% · above model

ROCKWELL AUTOMATION, INC

Deeply overvalued

Model IV$170.13

Premium +150% Return to IV: -60.0%

Owner yield 2.2% 10-yr IRR -1.3% · moderate

Market implies +18.6%/yr vs model +7.0% · above model

ROPER TECHNOLOGIES INC

Deeply undervalued

Model IV$995.98

Discount 63% Return to IV: +172.6%

Market implies -2.0%/yr vs model +12.2% · below model

Royalty Pharma plc

Deeply undervalued

Model IV$108.10

Discount 46% Return to IV: +85.0%

Market implies -4.4%/yr vs model +3.7% · below model

Revolution Medicines, Inc.

Market implies +125.3%/yr vs model +15.0% · above model

Deeply overvalued

Premium +233% Return to IV: -70.0%

Owner yield 2.1% 10-yr IRR -5.3% · steady

Market implies +19.1%/yr vs model +2.0% · above model

Scinai Immunotherapeutics Ltd.

Market implies +150.0%/yr vs model +15.0% · above model

Summit Therapeutics Inc.

Market implies +150.0%/yr vs model +15.0% · above model

SMITH & NEPHEW PLC

Discount 11% Return to IV: +12.4%

Owner yield 5.2% 10-yr IRR 6.7% · steady

Market implies +1.5%/yr vs model +3.6% · in line

Model IV$269.87

Discount 23% Return to IV: +30.4%

Owner yield 2.9% 10-yr IRR 6.5% · grower

Market implies +7.6%/yr vs model +13.6% · below model

Model IV$362.38

Discount 24% Return to IV: +32.2%

Owner yield 3.4% 10-yr IRR 6.1% · moderate

Market implies +4.8%/yr vs model +10.1% · below model

TAKEDA PHARMACEUTICAL CO LTD

BIO-TECHNE Corp

Deeply overvalued

Premium +246% Return to IV: -71.1%

Owner yield 2.0% 10-yr IRR -1.7% · moderate

Market implies +23.9%/yr vs model +7.9% · above model

Market implies +51.6%/yr vs model +2.0% · above model

TEVA PHARMACEUTICAL INDUSTRIES LTD

Deeply overvalued

Premium +185% Return to IV: -64.9%

Owner yield 2.0% 10-yr IRR -4.4% · steady

Market implies +17.9%/yr vs model +4.5% · above model

TENET HEALTHCARE CORP

Owner yield 7.4% 10-yr IRR 15.9% · moderate

Market implies -6.1%/yr vs model +8.6% · below model

THERMO FISHER SCIENTIFIC INC.

Deeply overvalued

Model IV$308.01

Premium +114% Return to IV: -53.2%

Owner yield 2.7% 10-yr IRR 0.8% · moderate

Market implies +15.5%/yr vs model +6.5% · above model

Deeply overvalued

Premium +378% Return to IV: -79.1%

Owner yield 3.4% 10-yr IRR 1.7% · steady

Market implies +25.5%/yr vs model +4.3% · above model

Trane Technologies plc

Deeply overvalued

Model IV$312.57

Premium +39% Return to IV: -27.9%

Owner yield 2.6% 10-yr IRR 4.4% · grower

Market implies +14.1%/yr vs model +12.4% · in line

Twist Bioscience Corp

Market implies +54.2%/yr vs model +29.9% · above model

10x Genomics, Inc.

Market implies +42.7%/yr vs model +7.0% · above model

UNIVERSAL HEALTH SERVICES INC

Deeply undervalued

Model IV$468.11

Discount 63% Return to IV: +167.9%

Owner yield 7.4% 10-yr IRR 19.3% · grower

Market implies -2.4%/yr vs model +12.8% · below model

UNITED THERAPEUTICS Corp

Deeply undervalued

Model IV$1,006.54

Discount 51% Return to IV: +104.1%

Owner yield 4.1% 10-yr IRR 12.0% · grower

Market implies +3.2%/yr vs model +15.1% · below model

Premium +1% Return to IV: -1.1%

Owner yield 3.8% 10-yr IRR 4.4% · steady

Market implies +5.2%/yr vs model +5.8% · in line

VERTEX PHARMACEUTICALS INC / MA

Deeply overvalued

Model IV$284.74

Premium +79% Return to IV: -44.2%

Owner yield 1.5% 10-yr IRR -3.0% · moderate

Market implies +16.7%/yr vs model +11.5% · above model

Discount 25% Return to IV: +33.5%

Owner yield 10.8% 10-yr IRR 17.2% · steady

Market implies -1.3%/yr vs model +2.9% · below model

WATERS CORP /DE/

Deeply overvalued

Model IV$153.22

Premium +177% Return to IV: -63.9%

Owner yield 2.1% 10-yr IRR -2.4% · moderate

Market implies +18.9%/yr vs model +6.2% · above model

WEST PHARMACEUTICAL SERVICES INC

Deeply overvalued

Model IV$123.32

Premium +193% Return to IV: -65.9%

Owner yield 1.5% 10-yr IRR -6.7% · steady

Market implies +19.0%/yr vs model +5.7% · above model

ZIMMER BIOMET HOLDINGS, INC.

Deeply undervalued

Model IV$203.72

Discount 54% Return to IV: +116.0%

Owner yield 7.2% 10-yr IRR 14.8% · moderate

Market implies -3.3%/yr vs model +7.8% · below model

Market implies +38.6%/yr vs model +33.5% · above model

Discount 20% Return to IV: +24.3%

Owner yield 5.7% 10-yr IRR 11.9% · moderate

Market implies +4.1%/yr vs model +8.7% · below model